TNKS
Human tankyrases (TNKS; EC 2.4.2.30), or TRF1-interacting ankyrin-related ADP-ribose polymerases, are specific PARPs that enhance telomerase access to telomeres, and post-translationally modify multiple proteins involved in processes including maintenance of telomere length, sister telomere association, and trafficking of glut4-containing vesicles.[1],[2]. Tankyrase 1 and tankyrase 2 are poly(ADP-ribosyl)ases that are distinguishable from other members of the enzyme family by the structural features of the catalytic domain, and the presence of a sterile α-motif multimerization domain and an ankyrin repeat protein-interaction domain[3].
[1] Y.J. Chiang et al. Tankyrase 1 and Tankyrase 2 Are Essential but Redundant for Mouse Embryonic Development. PLoSONE 2008, 3, e2639.
[2] H. Seimiya. The telomeric PARP, tankyrases, as targets for cancer therapy. Br. J. Cancer. 2006, 94, 341-345.
[3] L. Lehtiö et al. Tankyrases as drug targets. FEBS J. 2013, 280, 3576-3593.
| Axon ID | Name | Description | From price | |
|---|---|---|---|---|
| 3398 | E7449 mesylate | Potent, brain penetrable and orally bioavailable dual inhibitor of PARP1/2 and TNKS1/2 | €110.00 | |
| 2510 | IWR-1-endo | Inhibitor of the Wnt/β-catenin pathway strongly inhibiting TNKS1 and TNKS2 | €90.00 | |
| 1922 | JW 55 | Inhibitor of tankyrase (TNKS 1 and 2) | €95.00 | |
| 2599 | NVP-TNKS656 | Selective and orally active TNKS inhibitor and antagonist of Wnt pathway activity | €95.00 | |
| 1527 | XAV939 | Tankyrase (TNKS) inhibitor | €80.00 | |